Picture of Blueprint Medicines logo

BPMC — Blueprint Medicines Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapSucker Stock

Momentum

Relative Strength (%)
1m-14.49%
3m-26.63%
6m-44.08%
1yr-38.58%
Volume Change (%)
10d/3m+19.17%
Price vs... (%)
52w High-53.38%
50d MA-11.62%
200d MA-36.48%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-64.35%
Return on Equity-57.01%
Operating Margin-292.7%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for BPMC

What does the future hold for the Blueprint Medicines share price? background image

What does the future hold for the Blueprint Medicines share price?

The Blueprint Medicines (NSQ:BPMC) share price has risen by 14.9% over the past month and it’s currently trading at 74.42. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run wil...

Will the Blueprint Medicines share price run continue? background image

Will the Blueprint Medicines share price run continue?

In this article we will quickly re-cap the broker forecasts for Blueprint Medicines (NSQ:BPMC). The Blueprint Medicines share price has risen by 8.33% over the past month and it’s currently trading at 66.235. For investors considering...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Blueprint Medicines EPS forecast chart

Profile Summary

Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
October 14th, 2008
Public Since
April 30th, 2015
No. of Shareholders
11
No. of Employees
526
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
59,570,547

BPMC Share Price Performance

Upcoming Events for BPMC

Blueprint Medicines Corp Annual Shareholders Meeting

Blueprint Medicines Corp at Jefferies Healthcare Conference

Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference

Blueprint Medicines Corp at JMP Securities Life Sciences Conference (Virtual)

Blueprint Medicines Corp Annual Shareholders Meeting

Q2 2022 Blueprint Medicines Corp Earnings Release

Q3 2022 Blueprint Medicines Corp Earnings Release

Similar to BPMC

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email